Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 5/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | LIG1 | P18858 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746304 | 0.87 | DAO (0.46) | DAOCES1NSD2BCHELIG1 | |
| SCHEMBL4182713 | 0.83 | DAO (0.53) | DAOCES1NSD2BCHELIG1 | |
| SCHEMBL22525903 | 0.80 | CASP3 (0.52) | DAOCES1NSD2BCHELIG1 | |
| SCHEMBL22525287 | 0.76 | CASP3 (0.52) | DAOCASP3CASP2CASP7CASP6 | |
| SCHEMBL10648376 | 0.76 | LIG1 (0.49) | DAOCES1NSD2BCHELIG1 | |
| SCHEMBL6845708 | 0.75 | CES1 (0.60) | DAOCES1NSD2BCHELIG1 | |
| SCHEMBL3088689 | 0.75 | DAO (1.00) | DAOCES1NSD2BCHELIG1 | |
| SCHEMBL16133538 | 0.74 | DPP4 (0.36) | DAODPP4NR1H2NR1H3CA1 | |
| Hydrochloric Acid SCHEMBL11430657 | 0.73 | DAO (0.96) | DAOCES1NSD2BCHELIG1 | |
| SCHEMBL166123 | 0.72 | HPGD (0.47) | DAOCASP3CASP2CASP7CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-2134692-A2 | QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION | Wyeth a Corporation of the State of Delaware (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2132180-A1 | METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION | Wyeth a Corporation of the State of Delaware (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090076077-A1 | Methods and Compositions for Selectin Inhibition | WYETH (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076077-A1 | Methods and Compositions for Selectin Inhibition | WYETH (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076077-A1 | Methods and Compositions for Selectin Inhibition | WYETH (US) | 2009-03-19 | — | — | US | disclosed |
| US-7465799-B2 | Methods and compositions for selectin inhibition | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465799-B2 | Methods and compositions for selectin inhibition | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465799-B2 | Methods and compositions for selectin inhibition | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070244180-A1 | Substituted indole derivatives | SALMEDIX, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20060166947-A1 | Multiple myeloma treatments | DANA-FARBER CANCER INSTITUTE, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1682511-A2 | METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION | Wyeth (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | SALMEDIX, INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1680428-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1673373-A2 | INDOLE DERIVATIVES | Salmedix, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005047257-A2 | METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION | WYETH (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101568-A1 | Methods and compositions for selectin inhibition | WYETH (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005033112-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005033113-A2 | INDOLE DERIVATIVES | CEPHALON, INC (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244180-A1 | Substituted indole derivatives | IDO1, IDO2, HTR3A | DAO 1976/4885CES1 2278/4885NSD2 260/4885 |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | IL6, OPRK1, PTGES3 | DAO 941/4885CES1 594/4885NSD2 3069/4885 |
| US-20050101568-A1 | Methods and compositions for selectin inhibition | SELP, SELE, SELL | DAO 1610/4885CES1 707/4885NSD2 4259/4885 |
| US-20090076077-A1 | Methods and Compositions for Selectin Inhibition | SELP, SELE, SELL | DAO 1574/4885CES1 883/4885NSD2 4314/4885 |
| US-20060166947-A1 | Multiple myeloma treatments | BCL6, MCL1, BCL6B | DAO 3276/4885CES1 4591/4885NSD2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.